金穎生技1796.TW Overview
1796
金穎生技
0.32%
(0.00)
1796 Overall Performance
1796 AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
1796 Key Information
1796 Profile
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health care products in Taiwan and internationally. The company offers microbial fermentation products, which includes mushrooms, lactic acid bacteria, bacteria, yeast, and algae; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; packaging equipment; microbial fermentation toll manufacturing and consulting services. The company was founded in 1988 and is headquartered in Tainan City, Taiwan.
1796 FAQ
When is 1796's latest earnings report released?
The most recent financial report for 金穎生技 (1796) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1796's short-term business performance and financial health. For the latest updates on 1796's earnings releases, visit this page regularly.
Where does 1796 fall in the P/E River chart?
According to historical valuation range analysis, 金穎生技 (1796)'s current price-to-earnings (P/E) ratio is 168.84, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of 1796?
According to the latest financial report, 金穎生技 (1796) reported an Operating Profit of 6.49M with an Operating Margin of 3.92% this period, representing a growth of 161.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is 1796's revenue growth?
In the latest financial report, 金穎生技 (1796) announced revenue of 165.6M, with a Year-Over-Year growth rate of 25.57%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does 1796 have?
At the end of the period, 金穎生技 (1796) held Total Cash and Cash Equivalents of 275.46M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does 1796 go with three margins increasing?
In the latest report, 金穎生技 (1796) achieved the “three margins increasing” benchmark, with a gross margin of 26.69%%, operating margin of 3.92%%, and net margin of 3.41%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1796's profit trajectory and future growth potential.
Is 1796's EPS continuing to grow?
According to the past four quarterly reports, 金穎生技 (1796)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of 1796?
金穎生技 (1796)'s Free Cash Flow (FCF) for the period is 6.52M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 63.72% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.